1. Signaling Pathways
  2. Immunology/Inflammation
  3. Galectin

Galectin

Galectins comprise a family of soluble β-galactoside binding proteins, which regulate key biological processes including cell growth, differentiation, apoptosis, and immune responses.

Sixteen galectin genes have been identified in animal kingdoms, 12 of which are expressed in humans. Galectins are usually classified into three groups based on their structure: (i) prototypical galectins (galectin-1 (Gal1), Gal2, Gal5, Gal7, Gal10, Gal11, Gal 13, Gal14, and Gal15), characterized by a single CRD, which can act as monomers or form homodimers; (ii) the chimeric galectin Gal3 (the only member of this class), with a single CRD and a large amino-terminal domain that facilitates the formation of oligomers; (iii) the tandem repeat galectins, with two CRDs that are linked through a small peptide domain; this group includes Gal4, Gal6, Gal8, Gal9, and Gal12. Recently, Galectins have been implicated as major therapeutic determinants that confer sensitivity or resistance to a wide range of anticancer modalities including chemotherapy, radiotherapy, targeted therapies, antiangiogenic therapies, and immunotherapies.

Galectin Related Products (10):

Cat. No. Product Name Effect Purity
  • HY-114409
    GB1107
    Inhibitor 99.73%
    GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a Kd of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model.
  • HY-19756
    OTX008
    Inhibitor ≥98.0%
    OTX008 is a selective inhibitor of galectin-1.
  • HY-130208
    Thiodigalactoside
    Inhibitor ≥99.0%
    Thiodigalactoside (TDG) is an orally active and potent galectin (GAL) inhibitor with Kd values of 24 μM, 49 μM for GAL1 and GAL3, respectively. Thiodigalactoside, a non-metabolizable disaccharide, has anti-inflammatory and anti-cancer activity. Thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats.
  • HY-P1592A
    G3-C12 TFA
    99.45%
    G3-C12 (TFA) is a galectin-3 binding peptide, with Kd of 88 nM, and shows anticancer activity.
  • HY-147041
    GB1211
    Inhibitor
    GB1211 is an orally available galectin-3 (Gal-3) inhibitor.
  • HY-144312
    Galectin-3-IN-1
    Inhibitor
    Galectin-3-IN-1 (Compound 1) is a potent multivalent inhibitor of galectin-3 (Gal-3). Galectin-3 participates in many cancer-related metabolic processes.
  • HY-147865
    Apoptosis inducer 8
    Inhibitor
    Apoptosis inducer 8 (Compound 7c) is a galectin-1 (gal-1) mediated apoptosis-inducing agent against global major leading lung cancer burden. Apoptosis inducer 8 significantly reduced the gal-1 protein level. Apoptosis inducer 8 is also a PET imaging agent.
  • HY-P1592
    G3-C12
    99.44%
    G3-C12 is a galectin-3 binding peptide, with Kd of 88 nM, and shows anticancer activity.
  • HY-144313
    Galectin-3-IN-2
    Inhibitor
    Galectin-3-IN-2 (Compound 9) is a potent multivalent inhibitor of galectin-3 (Gal-3; IC50=8.3 μM). Galectin-3 participates in many cancer-related metabolic processes.
  • HY-146809
    Galectin-3 antagonist 2
    Galectin-3 is a β Galactoside specific carbohydrate recognition protein (lectin) has the ability to promote the migration of B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells and withstand drug therapy.